Targeted educational initiatives, better diagnostic pathways, and supportive policy measures may help narrow these gaps and promote more consistent evidence-based use of SGLT2 inhibitors in routine diabetes care. This evidence concerns the gene SLC5A2 and diabetes mellitus.